Biotechnology

CureVac BV

Disney

Conference Minutes

01913

SBDS

CVAC

The following are the minutes of the 4Q25FY earnings call for $Disney(DIS.US) compiled by Dolphin Research. For a review of the earnings report, please refer to the article &#34;Disney: Short-term Pressure but Guidance Unchanged, Can Iger Turn the Tide Before Leaving?&#34;1. Review of Core Financial Information1. DTC Net User Growth Rebounds Beyond Expectations: Streaming user growth continued to rebound in the fourth quarter, with Disney+ adding 4 million net new users (bundled packages) and Hulu adding 8.6 million (driven by the resumption of the Charter partnership and global brand expansion), both exceeding market expectations. The growth was mainly driven by high-quality content...

PRADA

Solo Brands

Dayforce

Ashland

Citigroup

Dominion Energy

NextDecade

Ameriprise Financial

PAR Tech

Disney (Minutes): Committed to double-digit percentage growth in earnings next year

Circle

CRCL

HSBA

00005

DEFI

HSBC

01763

APO-A

HSHD

The following are the Minutes of the $Citigroup(C.US)ircle (CRCL.US) FY25 Q3 earnings call. For a quick interpretation, you can simply review the Quick Interpretation of the financial report. 1. Financial Core Data Review: (1) Performance Overview: USDC circulation reached $73.7 billion, a year-on-year increase of 108%; on-chain transaction volume was $9.6 trillion, a year-on-year increase of 580%. (2) Profitability: Total revenue and reserve earnings were $740 million, a year-on-year increase of 66%; Adjusted EBITDA was $166 million, a year-on-year increase of 78%. The profit margin reached 57%...

Deutsche Boerse AG

HSBC Holdings Plc

HSBC HOLDINGS

Hashdex Bitcoin Futures ETF

Apollo Global

BlackRock

CIRC

SentinelOne

APOLLO GLOBAL MANAGEMENT INC 6.75% CONV PFD STK SER A

HSBC HK SDR 5to1

Circle (Minutes): The Ecological Network is More Important than Commercialization

BioNTech Completes Acquisition of CureVac to Enhance mRNA Capabilities

BioNTech SE announces acquisition of CureVac's certain rights

CureVac BV released FY2025 9 Months earnings on November 24 (EST), actual revenue USD 65.91 M, actual EPS USD 0.8589

CureVac BV released FY2025 Q3 earnings on November 24 (EST), actual revenue USD 63.49 M (forecast USD 25.1 M), actual EPS USD 1.7591 (forecast USD -0.1798)

CureVac BV released FY2025 Semi-Annual Earnings on August 15 (EST), actual revenue USD 2.408 M, actual EPS USD -0.5632

CureVac BV released FY2025 Q2 earnings on August 15 (EST), actual revenue USD 1.457 M (forecast USD 3.907 M), actual EPS USD -0.3096 (forecast USD -0.2128)

CureVac Announces Q2 2025 Financials and Reaches Agreement with BioNTech

UBS Downgrades CureVac Rating to Neutral

CureVac Annual General Meeting Passes All Proposals and Appoints New Members

Halper Sadeh Investigating Potential Misconduct at CureVac

Jefferies Downgrades CureVac Rating to Hold, Target Price to $5.00

JPMorgan Reiterates CureVac's Rating

CureVac NV Reports Strong 2024 Financials, Expanding mRNA R&D

CureVac BV released FY2025 Q1 earnings on May 20 (EST), actual revenue USD 966.66 K (forecast USD 3.732 M), actual EPS USD -0.2504 (forecast USD -0.2054)

CureVac Reports Q1 Earnings and Unveils R&D Progress

CureVac BV to release FY2025 Q1 earnings on May 19, 2025 (EST), forecast revenue USD 3.784 M, EPS USD -0.2072

CureVac's stock price rises, JMP maintains rating

CureVac BV released FY2024 annual earnings on April 11 (EST), actual revenue USD 575.85 M (forecast USD 573.8 M), actual EPS USD 0.7747 (forecast USD 0.6376)

CureVac BV released FY2024 Q4 earnings on April 11 (EST), actual revenue USD 264.39 M (forecast USD 22.53 M), actual EPS USD 0.7058 (forecast USD -0.1976)

CureVac BV released FY2024 Q3 earnings on April 11 After-Market EST, actual revenue USD 551.48 M (forecast USD 154.45 M), actual EPS USD 1.351 (forecast USD 0.4721)